UNITED THERAPEUTICS Corp 4

Dr. Victor J. Dzau was granted 730 restricted stock units and stock options for 2,300 shares of United Therapeutics Corporation common stock as equity compensation upon joining the Board.

On July 22, 2026, Dr. Victor J. Dzau, newly appointed to the Board of Directors of United Therapeutics Corporation, received an equity compensation package consisting of 730 restricted stock units (RSUs) and options to purchase 2,300 shares of common stock, all granted at no cost as part of the company’s Non-Employee Director Compensation Program. The RSUs represent the right to receive an equivalent number of common shares upon vesting, and the stock options carry an exercise price of $527.07 per share and expire on July 22, 2033. These awards are structured as (a) an initial grant of 380 RSUs and 1,190 options upon joining the Board and (b) a pro-rata grant of 350 RSUs and 1,110 options for the remainder of the 2026–2027 Board service year, with each component vesting in full on the one-year anniversary of the grant date. Following these grants, Dr. Dzau beneficially owns 730 RSUs and 2,300 stock options, all classified as directly held interests, with no open-market purchases or sales reported in the filing.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001201252-26-000010

Alert Tier

5